Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature
© Corcoran et al.; licensee BioMed Central Ltd. 2012
Received: 20 May 2012
Accepted: 18 July 2012
Published: 18 July 2012
A 54 year old lady presented for routine excision of a scalp lesion thought clinically to represent a sebaceous cyst of the right occiput. 4 years earlier she underwent total abdominal hysterectomy and right salpingo-oophorectomy for 3 large uterine fibroids. Histo-pathological examination of the hysterectomy specimen revealed an incidental low-grade leiomyosarcoma. Staging imaging was negative for metastatic disease. She made an uneventful recovery and was treated further by adjuvant pelvic radiotherapy.
She noticed an uncomfortable and unsightly cystic swelling on her occiput four years after hysterectomy and was referred for routine excision of what was believed to be a benign lesion. The lesion was excised and sent for histopathological examination. Microscopic analysis including immuno-histochemistry demonstrated an ER and PR positive metastatic deposit of leiomyosarcoma. The margins of excision were histologically clear of disease.
At Multi-Disciplinary Team (MDT) discussion a diagnosis of metastatic scalp deposit from previous uterine leiomyosarcoma was made. Re-staging CT brain, thorax, abdomen and pelvis and MRI brain were negative for local recurrence or distant metastases. She is currently undergoing radiotherapy to the scalp and surrounding tissues and will be followed up closely by the involved teams.
To the best of our knowledge, this is the first case described in the worldwide literature of isolated cutaneous metastasis to the scalp of uterine leiomyosarcoma without evidence of disseminated disease at other sites.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1311834987345566
KeywordsSarcoma Leiomyosarcoma Uterine leiomyosarcoma ULMS Metastasis Metastatic uterine leiomyosarcoma Scalp Cutaneous metastasis Atypical metastasis Progesterone receptor PR p53
At Multi-Disciplinary Team (MDT) discussion with input from pathologists, medical oncologists, radiation oncologists and surgeons, including review of the original hysterectomy sides, a confirmed diagnosis of metastatic scalp deposit from previous uterine leiomyosarcoma was made. Re-staging CT brain, thorax, abdomen and pelvis and MRI brain were negative for local recurrence or distant metastases. She is currently undergoing radiotherapy to the scalp and surrounding tissues, and may require salvage adjuvant chemotherapy at a future date if other sites of metastatic disease are detected.
Leiomyosarcoma is a rare and unpredictable malignancy of smooth muscle. Soft tissue sarcomas account for 0.7% of all malignancies and leiomyosarcoma accounts for 5-10% of these cases . Leiomyosarcoma can occur in soft tissue, skin, blood vessels and bone , and are histologically similar irrespective of location. The most common site of leiomyosarcoma of soft tissue is the retroperitoneum, accounting for 50% of all cases . Metastasis of sarcoma occurs by haematogenous spread , so cutaneous metastasis is an unusual discovery.
The definition of a cutaneous metastasis is “a neoplastic lesion arising from another neoplasm with which there is no longer continuity” . These lesions account for 0.7% to 9% of all metastases . More than half of cutaneous metastases arise from breast (51%) and almost one fifth (18%) from melanoma . Cutaneous metastasis occurs less commonly in malignancies such as leukaemia and lymphoma, and metastasis of various types of sarcomas accounts for only 2–3% of all metastatic skin lesions .
Port site metastasis has been described in colorectal , gallbladder , gastric , ovarian  and lung cancer . These tumors can be broadly categorised as cutaneous metastases but are entirely different in etiology and can be explained by transcoelomic spread or direct contamination [13, 14].
Uterine leiomyosarcoma (ULMS) is an uncommon malignancy accounting for approximately 1% of uterine cancer  with an estimated annual incidence of 0.64 per 100,000 women . Although leiomyosarcoma has also been described elsewhere in the pelvis including the cervix  and urinary bladder , it is more commonly found in the uterus. ULMS have high metastatic potential and 5 year survival rates vary from 0% to 73% in the literature [19–21]. Distant metastatic spread of ULMS has been described in lung , abdomen , soft tissue, and brain . Less common metastatic sites include the breast  and bone . Interestingly, another pathological entity, Benign Metastasizing Leiomyoma (BML) of the uterus describes metastasis of benign leiomyoma to the lung years post hysterectomy for uterine leiomyoma in pre-menopausal women. One study by Kayser et al . examined 10 cases of BML and showed median survival was 94 months in BML patients and just 22 months in corresponding cases of confirmed lung metastasis of ULMS. BML patients can expect a much better prognosis than those with metastatic ULMS.
Cutaneous metastasis of ULMS is exceptionally rare and there is a paucity of information in the literature.
To the best of our knowledge only 4 cases of scalp metastasis of ULMS have been described worldwide [28–31]. The first reported case of ULMS with scalp metastases was described by Gardiner in 1917, and in this case the patient had perished and autopsy showed widespread metastasis involving the lungs, liver, pancreas and bone . Another case involved disseminated intra-abdominal metastases and multiple cutaneous lesions . A further case was described with cutaneous metastases involving both scalp and back . In 2010 a case of primary ULMS with histologically confirmed scalp metastasis was published , but in this case there was also a history of disseminated disease from the primary uterine tumor and the patient had undergone pulmonary lobectomy for metastatic lung nodules. Our case of single cutaneous scalp metastasis from primary uterine leiomyosarcoma without evidence of other sites of disease spread is the first of its kind ever described worldwide.
One theory postulated by several authors explaining how a uterine leiomyosarcoma could metastasize to the scalp is haematogenous spread via Batson’s Plexus. This plexus was first described by anatomist Oscar Vivian Batson in 1940 and describes spread of tumour cells through the deep pelvic veins to the internal vertebral venous plexuses. Batson’s vertebral venous plexus consists of four interconnected venous networks surrounding the vertebral column. These valveless, thin walled, low pressure veins bypass the pulmonary, caval and portal venous systems, so this could provide an aberrant pathway of haematogenous spread by tumor in the pelvis to the head and neck [32–34].
The diagnostic value of progesterone receptor (PR) and p53 expression in ULMS is still under investigation. PR expression is useful in classifying leiomyosarcoma (LMS) vs. smooth muscle tumors of uncertain malignant potential (STUMP), Leiomyoma (LM) and Atypical Leiomyoma (ALM). A recent study  published in 2012 showed a prominent difference in PR expression between LMS and STUMP, and also demonstrated that ALMs had a similar PR staining pattern to LM. Thus, progesterone receptor expression can aid in effectively distinguishing both ALMs and STUMP from LMS. This study also showed low immunostaining rates of PR in LMS, which is consistent with previous studies. The study also examined the expression of p53, a tumor suppressor gene in LMS. Intense staining was described in the leiomyosarcoma samples, while other smooth muscle tumors, including STUMP, showed poor staining. Therefore p53 was shown clearly to be an indicator of malignancy. Overall PR and p53 staining allow for more accurate pathological diagnosis and therefore optimal management of such tumors can be achieved.
Evidence basis for treatment
Regarding treatment of recurrent or metastatic uterine leiomyosarcoma, surgical resection should be strongly considered in patients with localized single foci recurrences, either local or metastatic. In one study of 41 women who underwent resection for recurrent ULMS (17 local, 18 distant, 6 both), a two-year survival of 71% was reported in those patients who had a disease-free interval of 12 months or longer between resection of the primary tumor and the diagnosis of metastatic disease. Optimal surgical resection may provide an opportunity for long-term survival in these patients .
Single agent doxorubicin has been shown to be somewhat successful in combating advanced ULMS. There have been two randomized trails showing the efficacy of doxorubicin single agent chemotherapy vs. combination chemotherapy. Doxorubicin proved as effective as a single agent vs. doxorubicin plus cyclphosphamide as response rates, and median overall survival (median 11.6 vs. 10.9 months) were similar in both arms for patients with measurable disease . In another study comparing single agent Doxorubicin vs. combination Doxorubicin and Dacarbazine, Doxorubicin single agent therapy was also shown to as effective in terms of progression-free survival or overall survival (7.7 versus 7.3 months), although overall response rate was higher in the combination therapy patient group . The most successful chemotherapeutic regime for combating advanced ULMS to date in patients with un-resectable uterine or other primary site ULMS is Gemcitabine and Docetaxel which has been shown to have an overall response rate of 53% and a mild toxicity profile, although this regime should be used in combination with a granulocyte colony stimulating factor to counteract neutropaenia .
Postoperative adjuvant radiotherapy (RT) for advanced uterine leiomyosarcoma has been suggested by the European Organization for Research and Treatment of Cancer to have lower rates of local recurrence but no improvement in long term survival . A retrospective study published in 1999, the largest series of its type, evaluated 103 women with uterine sarcoma (42% ULMS) who were treated with adjuvant radiotherapy. It was shown that irradiated patients had a higher rate of pelvic control than the control group (73% vs. 36%) combined with an increase in overall survival (73% vs. 37%) . As yet there are no large studies evaluating the efficacy of radiotherapy in ULMS with confirmed distant metastases so each case must be discussed at multi-disciplinary team conference and managed accordingly.
Clinically, patients with cutaneous metastasis of leiomyosarcoma present with cyst like structures underneath the skin as in our case, or as cutaneous nodules . In the context of a previous histological diagnosis of leiomyosarcoma caution should be exercised to remove any suspicious skin lesions for histopathological analysis. Due to the rarity of these cutaneous metastases and the lack of studies in this area, there is no specific guideline as to the optimal extent of an oncologically safe margin. Initial aggressive resection with wide margins is advised and restaging imaging is essential to rule out other metastatic disease. Although exceptionally rare, physicians, dermatologists and surgeons should keep in mind the metastatic potential of leiomyosarcoma to the skin.
Written informed consent was obtained from the patient for publication of this Case Report and accompanying images.
- Gustafson P, Willen H, Baldetrop B, et al.: Soft tissue leiomyosarcoma: a population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer. 1992, 70: 114-10.1002/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U.View ArticlePubMedGoogle Scholar
- Golden T, Stout AP: Smooth muscle tumors of the gastrointestinal tract and retroperitoneal tissues. Surg Gynecol Obstet. 1941, 73: 784Google Scholar
- Rao UM, Hanan AH, Karakousis CP, et al.: Distant skin and soft tissue metastases from sarcomas. J Surg Oncol. 1998, 69: 94-98. 10.1002/(SICI)1096-9098(199810)69:2<94::AID-JSO9>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Schwartz RA: Cutaneous metastatic disease. J Am Acad Dermatol. 1995, 33: 161-182. 10.1016/0190-9622(95)90231-7.View ArticlePubMedGoogle Scholar
- Rolz-Cruz G, Kim CC: Tumor invasion of the skin. Dermatol Clin. 2008, 26: 89-102.View ArticlePubMedGoogle Scholar
- Lookingbill DP, Spangler N, Helm KF: Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients. J Am Acad Dermatol. 1993, 29: 228-236. 10.1016/0190-9622(93)70173-Q.View ArticlePubMedGoogle Scholar
- Spencer PS, Helm TN: Skin metastases in cancerpatients. Cutis. 1987, 69: 119-121.Google Scholar
- Wexner SD, Cohen SM: Port site métastases after laparoscopic colorectal surgery for cure of malignancy. Br J Surg. 1995, 82: 295-298. 10.1002/bjs.1800820305.View ArticlePubMedGoogle Scholar
- Drouard F, Delamarre J, Capron J: Cutaneous seeding of gallbladder cancer after laparoscopic cholecystectomy. N Engl J Med. 1991, 325: 1316PubMedGoogle Scholar
- Cava A, Roman J, Quintela G, et al.: Subcutaneous métastases following laparoscopy in gastric adenocarcinoma. Eur J Surg Oncol. 1990, 16: 63-67.PubMedGoogle Scholar
- Miralles RM, Petit J, Baraguere L: Metastatic carcinoma spread at the laparoscopic puncture site. Report of a case in a patient with carcinoma of the ovary. Eur J Gynecol Oncol. 1989, 19: 442Google Scholar
- Johnstone PAS, Rohde DC, Swartz SE, et al.: Port site recurrences after laparoscopic and thorascopic procedures in malignancy. J Clin Oncol. 1996, 14: 1950-1956.PubMedGoogle Scholar
- Whelan RL, Lee SW: Review of investigations regarding the etiology of port site tumor recurrence. J Laparoendosc Adv Surg Tech A. 1999, 9 (1): 1-16. 10.1089/lap.1999.9.1.View ArticlePubMedGoogle Scholar
- Leather AJ, Kocjan G, Savage F, et al.: Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum. 1994, 37: 814-819. 10.1007/BF02050147.View ArticlePubMedGoogle Scholar
- Norris HJ, Zaloudek CJ: Mesenchymal tumors of the uterus. In Pathology of the female genital tract. Edited by: Blaustein A. 1982, Springer, New York, 352-Secondth editionView ArticleGoogle Scholar
- Harlow BL, Weis NS, Lofton S: The epidemiology of sarcoma of the uterus. J Natl Cancer Inst. 1986, 76: 399PubMedGoogle Scholar
- Fadare O: Uncommon sarcomas of the uterine cervix: a review of selected entities. Diagn Pathol. 2006, 1: 30-35. 10.1186/1746-1596-1-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Li YF, Yu CP, Wu ST, Dai MS, Lee HS: Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review. Diagn Pathol. 2011, 6 (1): 35-10.1186/1746-1596-6-35.PubMed CentralView ArticlePubMedGoogle Scholar
- Bartsich EG, Bowe ET, Moore GT: Leiomyosarcomas of the uterus: a 50-year review of 42 cases. Obstet Gynecol. 1988, 71: 845Google Scholar
- Hart RW, Billman JK: A reassessment of uterine neoplasms originally diagnosed as leiomyosarcoma. Cancer. 1902, 1978: 41Google Scholar
- Van Dinh T, Woodruff JO: Leiomyosarcoma of the uterus. Am J Obstet Gynecol. 1982, 144: 817PubMedGoogle Scholar
- Nishida T, Shoji S, Itoh T, et al.: Metastatic lung tumor from uterine leiomyosarcoma. Kyobu Geka. 2006, 59 (13): 1191-1196.PubMedGoogle Scholar
- Saylam B, Özozan ÖV, Düzgün AP, et al.: Perforated intestinal leiomyosarcoma as a metastasis of uterine leiomyosarcoma: a case report. Cases J. 2009, 17: 2-9288.Google Scholar
- Yamada S, Yamada SM, Nakaguchi H, et al.: A case of multiple brain metastases of uterine leiomyosarcoma with a literature review. Surg Oncol. 2011, 20 (4): e127-e131. 10.1016/j.suronc.2011.04.001.View ArticlePubMedGoogle Scholar
- Sibartie S, Larkin JO, Lee G, et al.: Metastatic uterine leiomyosarcoma presenting as a breast lump. Ir J Med Sci. 2011, 180 (4): 889-891. 10.1007/s11845-009-0286-8.View ArticlePubMedGoogle Scholar
- Chi-Man Y, Kuo-Chung Y, Yu-Shing L, et al.: Skull Metastasis from Uterine Leiomyosarcoma: A Case Report. World J Surgical Oncology. 2009, 7: 45-10.1186/1477-7819-7-45.View ArticleGoogle Scholar
- Kayser K, Zink S, Schneider T, et al.: Benign metastasizing leiomyoma of the uterus: documentation of clinical, immunohistochemical and lectin-histochemical data of ten cases. Virchows Arch. 2000, 437 (3): 284-292. 10.1007/s004280000207.View ArticlePubMedGoogle Scholar
- Gardner LV: A case of metastatic leiomyosarcoma primary in the uterus. J Med Res. 1917, 20: 19-29.Google Scholar
- Chun-Hua W, Gwo-Shing C, Hui-Hua H, et al.: Uterine Leiomyosarcoma Metastatic to the Scalp —A Case Report and Review of the Literature. Dermatol Sinica. 2004, 22: 69-73. 2004Google Scholar
- Alessi E, Innocenti M, Sala F: Leiomyosarcoma metastatic to the back and scalp from a primary neoplasm in the uterus. Am J Dermatopathol. 1985, 7: 471-476. 10.1097/00000372-198510000-00012.View ArticlePubMedGoogle Scholar
- Lee HE, Jue MS, Ko JY, et al.: A Case of Uterine Leiomyosarcoma Metastasized to the Skin: Local Recurrence and Rapid Growth after Excision. Korean J Dermatology. 2010, 48 (4): 346-349.Google Scholar
- Maheshwari GK, Baboo HA, Wadhwa MK, et al.: Scalp metastasis from squamous cell carcinoma of the cervix. Int J Gynecol Cancer. 2001, 11: 244-246. 10.1046/j.1525-1438.2001.00074.x.View ArticlePubMedGoogle Scholar
- Snow T, Madjar D, Bentz M, et al.: Renal Cell Carcinoma Metastatic to the scalp: Case Report and Review of the Literature. Dermatol Surg. 2001, 27: 192-194.PubMedGoogle Scholar
- Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940, 112: 138-149. 10.1097/00000658-194007000-00016.PubMed CentralView ArticlePubMedGoogle Scholar
- Hewedi IH, Radwan NA, Shash LS: Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors. Diagn Pathol. 2012, 7: 1-10.1186/1746-1596-7-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Leitao MM, Brennan MF, Hensley M, et al.: Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol. 2002, 87: 287-10.1006/gyno.2002.6840.View ArticlePubMedGoogle Scholar
- Muss HB, Bundy B, DiSaia PJ, et al.: Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985, 55: 1648-10.1002/1097-0142(19850415)55:8<1648::AID-CNCR2820550806>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Omura GA, Major FJ, Blessing JA, et al.: A randomized study of adriamycin with and without dimethyl trizenoimidazole carbozamide in advanced uterine sarcomas. Cancer. 1983, 52: 626-10.1002/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E.View ArticlePubMedGoogle Scholar
- Hensley ML, Maki R, Venkatraman E, et al.: Gemcitabine and Docetaxel in patients with unresectable leiomyosarcoma: the result of a phase II trial. J Clin Oncol. 2002, 20: 2824-10.1200/JCO.2002.11.050.View ArticlePubMedGoogle Scholar
- Reed NS, Mangioni C, Malmstrom H, et al.: First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. an EORTCGCG study. Int J Gynecol Cancer. 2003, 13: 4Google Scholar
- Ferrer F, Sabater S, Farrus B, et al.: Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Group Oncologic Catala-Occita. Int J Radiat Oncol Bio Phys. 1999, 44: 47-10.1016/S0360-3016(98)00515-X.View ArticleGoogle Scholar
- Barbetakis N, Paliouras D, Asteriou C, et al.: Cutaneous skull metastasis from uterine leiomyosarcoma: a case report. World J Surg Oncol. 2009, 7: 45-10.1186/1477-7819-7-45.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.